• Prévention

  • Politiques et programmes de prévention

  • Poumon

Pairing smoking cessation with lung cancer screening may save lives

Cet article passe en revue les études estimant qu'associer le dépistage du cancer du poumon à une intervention de sevrage tabagique pourrait prévenir plus de décès par cancer du poumon que le dépistage seul

A new study has found that offering smoking cessation interventions to current smokers simultaneously with lung cancer screenings provides more years of lifesaving benefit than screening alone at very little added expense. The study appeared in the Journal of the National Cancer Institute (JNCI; published online January 23, 2021. doi:10.1093/jnci/djab002). The Centers for Medicare and Medicaid Services and guidelines from national health organizations, including the American Cancer Society, recommend that smoking cessation methods should be offered at the same time as lung cancer screening. However, in current lung screening clinical practice, cessation interventions are often omitted, in part because of uncertainty regarding their incremental benefit and cost-effectiveness. In a related article written by many of the same authors and published at approximately the same time in the Journal of Thoracic Oncology (2020;15:1160-1169. doi:10.1016/j.jtho.2020.02.008), the researchers note that approximately 50% of screen-eligible individuals are current smokers, and they estimate that combined use of screening and a cessation intervention with a 10% quit rate might prevent 14% more lung cancer deaths than screening alone. The current JNCI study extends that research to estimate the cost-effectiveness of adding cessation interventions to lung cancer screening. Rafael Meza, PhD, senior study author of the JNCI study and an associate professor at the Department of Epidemiology of the University of Michigan in Ann Arbor, Michigan, says that, “Our analysis [in the JNCI study], including comparisons between different approaches, shows that cessation programs within lung cancer screening greatly expand the benefits of lung cancer at a reasonable cost making it even more cost-effective.”

CA: A Cancer Journal for Clinicians 2021

Voir le bulletin